GlaxoSmithKline plc (GSK.L)

LSE - LSE Delayed Price. Currency in GBp

Add to watchlist

1,415.00-8.40 (-0.59%)

At close: 4:35PM BST

Full screen

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

View all chart patterns

Performance Outlook

Previous Close	1,423.40
Open	1,418.40
Bid	1,412.20 x 0
Ask	1,412.20 x 0
Day's Range	1,406.68 - 1,426.40
52 Week Range	1,190.80 - 1,677.40
Volume	4,856,682
Avg. Volume	9,558,845

Market Cap	71.196B
Beta (5Y Monthly)	0.36
PE Ratio (TTM)	13.58
EPS (TTM)	104.20
Earnings Date	Jul 28, 2021
Forward Dividend & Yield	0.80 (5.62%)
Ex-Dividend Date	May 20, 2021
1y Target Est	1,644.50

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

N/A

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Editor's Pick
Yahoo Finance Video
Delta COVID-19 variant likely to become dominant U.S. strain: Doctor
Dr. Susannah Hills, Pediatric Airway surgeon and assistant professor of ENT at Columbia University Medical Center, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
- Numbers Still Small, But More Transmissible Delta Variant Grew Nearly 30% Last Week In California
  Deadline
- Concerns Rise That Delta Variant May Become Predominant Coronavirus Strain in the U.S.
  The Root
Benzinga
GlaxoSmithKline CEO Struggling To Get Key Shareholders In Her Favor Amid Pressure From Hedge Fund Activist Elliott Management
GlaxoSmithKline Plc's (NYSE: GSK) CEO Emma Walmsley struggled to win over key shareholders after Elliott Management attracted converts for radical change at the company, the Financial Times reported citing leading investors. Ahead of GSK's investor day on Wednesday (23 June), activist investor Elliott has sown doubt about whether Walmsley should stay to lead through the transformation planned after it spun off its consumer health division last year. "Her background is in the consumer rather than
Benzinga
GSK - Vir Biotech's Sotrovimab Reduces Hospitalization, Risk Of Death In Adult COVID-19 Patients
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced final, confirmatory results from the Phase 3 COMET-ICE evaluating sotrovimab in high-risk adult outpatients with mild-to-moderate COVID-19. Data demonstrated a 79% reduction in hospitalization for more than 24 hours or death compared with placebo after 29 days. The most common adverse events observed in the sotrovimab treatment group were rash (1%) and diarrhea (2%), all mild or moderate. No other treatment-em
- Gilead says real-world data show COVID-19 drug Veklury can reduce the risk of death
  MarketWatch
- Study confirms GSK-Vir antibody drug reduces hospitalization, death in COVID-19 patients
  Reuters